Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 853-861

  Kepka, Lucyna ^a   Tyc Szczepaniak, Dobromira ^a   Bujko, Krzysztof ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Accelerated radiotherapy; Hypofractionation; Non small cell lung cancer; Simultaneous boost

Indexed keywords

CISPLATIN; CORTICOSTEROID; NAVELBINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CLINICAL EVALUATION; COMPUTER ASSISTED RADIOTHERAPY; ESOPHAGUS DISEASE; FEMALE; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; THERAPY EFFECT; THREE DIMENSIONAL IMAGING; TREATMENT DURATION;

EID: 68549121087     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a97dda     Document Type: Article

References (29)

1. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;133:243S-265S. (Pubitemid 47502811)
2. Jassem J. The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol 2007;83:203-213. (Pubitemid 46776921)
3. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004:CD002140.
4. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small call lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006;66:1399-1407. (Pubitemid 44778943)
5. Kepka L, Danilova V, Saghatelyan T, et al. Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer 2007;56:235-245. (Pubitemid 46591989)
6. Mehta M, Scrimger R, Mackie TR, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2001;49:23-33. (Pubitemid 32041273)
7. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27: 131-146. (Pubitemid 18168463)
8. Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol 2001;40:712-717.
9. Thomas CR, Giroux DJ, Stelzer KJ, et al. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229). Int J Radiat Oncol Biol Phys 1998;40: 1039-1047.
10. Lester JF, Macbeth FR, Brewster AE, Court JB, Iqbal N. CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer. Lung Cancer 2004;45:237-242. (Pubitemid 38891487)
11. Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 1996;41: 41-44.
12. Thirion P, Holmberg O, Collins CD, et al. Escalated dose for non-smallcell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 2004;71:163-166. (Pubitemid 38521184)
13. Sun LM, Wan Leung S, Wang CJ, et al. Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study. Int J Radiat Oncol Biol Phys 2000;47: 413-418.
14. Uitterhoeve LLJ, Belderbos JSA, Koolen MGJ, et al. Toxicity of high dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. Eur J Cancer 2000;36:592-600.
15. Belderbos JSA, Uitterhoeve LLJ, van Zandwijk N, et al. Randomized trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007;43:114-121 (Pubitemid 46054477)
16. Bradley JD, Graham M, Suzanne S, et al. Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC. J Clin Oncol 2005;23:7063S.
17. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993;27:493-498 (Pubitemid 23331113)
18. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced nonsmall- cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005;63:667-671. (Pubitemid 41400050)
19. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137-148. (Pubitemid 29461081)
20. Sause W, Kolesar P, Taylor SIV, et al. Final results of phase III trials in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364. (Pubitemid 30111583)
21. Baumann M, Herrmann T, Koch R, Strelocke K, Paul U. Continuous hyperfractionated accelerated radiotherapy-weekend less (CHARTWEL) versus conventionally fractionated (CF) in non-small-cell lung cancer (NSCLC): first results of a phase III randomised multicentre trial (ARO 97-1). Eur Journal Cancer 2005;3:S323.
22. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-328. (Pubitemid 40164423)
23. Kong FM, Ten Haken R, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable non-small-cell lung cancer: long term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63:324-333. (Pubitemid 41317147)
24. Belderbos JSA, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:126-134. (Pubitemid 44175671)
25. Yuan S, Sun X, Li M, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007;30:239-244. (Pubitemid 46884142)
26. Belderbos JS, Kepka L, Spring Kong FM, Martel MK, Videtic GM, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008;72:335-342.
27. Kepka L, Bujko K, Zolciak-Siwinska A. Risk of isolated nodal failure for non-small cell lung cancer (NSCLC) treated with the elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) techniques. Acta Oncol 2008;47:95-103.
28. Kepka L, Bujko K, Zolciak-Siwinska A, Garmol D. Incidental irradiation of mediastinal and hilar lymph node stations during 3D-conformal radiotherapy for non-small cell lung cancer. Acta Oncol 2008;47:954-961. (Pubitemid 351882731)
29. Videtic GM, Rice TW, Murthy S, et al. Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort. Int J Radiat Oncol Biol Phys 2008;72:702-706.